Capricor Therapeutics, Inc.
CAPR
$8.64
-$0.42-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 5.44% | 18.35% | |||
| Gross Profit | -5.44% | -18.35% | |||
| SG&A Expenses | 49.85% | 55.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.79% | 26.12% | |||
| Operating Income | -16.79% | -26.12% | |||
| Income Before Tax | -20.01% | -12.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.01% | -12.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.01% | -12.50% | |||
| EBIT | -16.79% | -26.12% | |||
| EBITDA | -16.96% | -26.47% | |||
| EPS Basic | -18.98% | 4.31% | |||
| Normalized Basic EPS | -19.27% | 4.53% | |||
| EPS Diluted | -18.98% | 4.31% | |||
| Normalized Diluted EPS | -19.27% | 4.53% | |||
| Average Basic Shares Outstanding | 0.86% | 17.57% | |||
| Average Diluted Shares Outstanding | 0.86% | 17.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||